pmc logo image
Logo of aacAntimicrob Agents Chemother SubscriptionsAntimicrob Agents Chemother Web Site

Formats:

Antimicrob Agents Chemother. 1990 March; 34(3): 442–447.
PMCID: PMC171612
Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients.
M H Chandler, S M Toler, R P Rapp, R R Muder, and J A Korvick
College of Pharmacy, University of Kentucky, Lexington 40536-0082.
Abstract
The purpose of this clinical study was to investigate the influence of concomitant drug therapy with ciprofloxacin and rifampin on the individual pharmacokinetic profile of each agent in elderly patients. Twelve nursing home patients (age, 74 +/- 7 years), colonized with methicillin-resistant Staphylococcus aureus, were randomized to receive 14-day therapy with oral ciprofloxacin (750 mg every 12 h) (group A; n = 6) or ciprofloxacin (750 mg every 12 h) and oral rifampin (300 mg every 12 h) (group B; n = 6). Serial blood samples were obtained from 0 to 12 h following ciprofloxacin doses 1 and 13 and from 0 to 36 h after the last ciprofloxacin dose. No significant differences (P greater than 0.05) were found between or within groups in any pharmacokinetic parameter. The mean ciprofloxacin oral clearance values were 0.35 +/- 0.06, 0.41 +/- 0.15, and 0.38 +/- 0.11 liter/h per kg for doses 1, 13, and 28, respectively, in group A patients. The mean oral clearance values in group B patients for the respective doses were 0.53 +/- 0.36, 0.32 +/- 0.13, and 0.36 +/- 0.17 liter/h per kg. Likewise, no significant differences (P greater than 0.05) in rifampin pharmacokinetic parameters were found when compared with historical controls. These data suggest that ciprofloxacin and rifampin may be given concomitantly in standard clinical dosing regimens. The combination results in therapeutic levels of both drugs and appears to be safe for administration to elderly nursing home patients.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1012K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis. 1983 Jul–Aug;5 Suppl 3:S428–S432. [PubMed]
  • Advenier C, Gobert C, Houin G, Bidet D, Richelet S, Tillement JP. Pharmacokinetic studies of rifampicin in the elderly. Ther Drug Monit. 1983;5(1):61–65. [PubMed]
  • Baciewicz AM, Self TH. Rifampin drug interactions. Arch Intern Med. 1984 Aug;144(8):1667–1671. [PubMed]
  • Barriere SL, Kaatz GW, Seo SM. Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits. Antimicrob Agents Chemother. 1989 Apr;33(4):589–590. [PubMed]
  • Beers M, Avorn J, Soumerai SB, Everitt DE, Sherman DS, Salem S. Psychoactive medication use in intermediate-care facility residents. JAMA. 1988 Nov 25;260(20):3016–3020. [PubMed]
  • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. [PubMed]
  • Gasser TC, Ebert SC, Graversen PH, Madsen PO. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function. Antimicrob Agents Chemother. 1987 May;31(5):709–712. [PubMed]
  • Guay DR, Awni WM, Peterson PK, Obaid S, Stein D, Breitenbucher R, Matzke GR. Single and multiple dose pharmacokinetics of oral ciprofloxacin in elderly patients. Int J Clin Pharmacol Ther Toxicol. 1988 Jun;26(6):279–284. [PubMed]
  • Haley RW, Hightower AW, Khabbaz RF, Thornsberry C, Martone WJ, Allen JR, Hughes JM. The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit. Ann Intern Med. 1982 Sep;97(3):297–308. [PubMed]
  • Henry NK, Rouse MS, Whitesell AL, McConnell ME, Wilson WR. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med. 1987 Apr 27;82(4A):73–75. [PubMed]
  • Jezequel AM, Orlandi F, Tenconi LT. Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes. Gut. 1971 Dec;12(12):984–987. [PubMed]
  • Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev. 1981;12(1):159–218. [PubMed]
  • Lecaillon JB, Febvre N, Metayer JP, Souppart C. Quantitative assay of rifampicin and three of its metabolites in human plasma, urine and saliva by high-performance liquid chromatography. J Chromatogr. 1978 Mar 1;145(2):319–324. [PubMed]
  • Lu AY, Ryan D, Kawalek J, Thomas P, West SB, Huang MT, Levin W. Multiplicity of liver microsomal cytochrome P-450: separation, purification and characterization. Biochem Soc Trans. 1976;4(1):169–172. [PubMed]
  • Mandell GL. The antimicrobial activity of rifampin: emphasis on the relation to phagocytes. Rev Infect Dis. 1983 Jul–Aug;5 Suppl 3:S463–S467. [PubMed]
  • Mattila KS, Kuusela V, Pelliniemi TT, Rajamäki A, Kaihola HL, Juva K. Haematological laboratory findings in the elderly: influence of age and sex. Scand J Clin Lab Invest. 1986 Sep;46(5):411–415. [PubMed]
  • Nix DE, De Vito JM, Schentag JJ. Liquid-chromatographic determination of ciprofloxacin in serum and urine. Clin Chem. 1985 May;31(5):684–686. [PubMed]
  • Raoof S, Wollschlager C, Khan FA. Ciprofloxacin increases serum levels of theophylline. Am J Med. 1987 Apr 27;82(4A):115–118. [PubMed]
  • Riesenberg D. Drugs in the institutionalized elderly: time to get it right? JAMA. 1988 Nov 25;260(20):3054–3054. [PubMed]
  • Rubinstein E, Segev S. Drug interactions of ciprofloxacin with other non-antibiotic agents. Am J Med. 1987 Apr 27;82(4A):119–123. [PubMed]
  • Salem SA, Rajjayabun P, Shepherd AM, Stevenson IH. Reduced induction of drug metabolism in the elderly. Age Ageing. 1978 May;7(2):68–73. [PubMed]
  • Schwartz J, Jauregui L, Lettieri J, Bachmann K. Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum. Antimicrob Agents Chemother. 1988 Jan;32(1):75–77. [PubMed]
  • Stille W, Harder S, Mieke S, Beer C, Shah PM, Frech K, Staib AH. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J Antimicrob Chemother. 1987 Nov;20(5):729–734. [PubMed]
  • Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther. 1986 May;39(5):489–490. [PubMed]
  • Twum-Barima Y, Finnigan T, Habash AI, Cape RD, Carruthers SG. Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol. 1984 May;17(5):595–597. [PubMed]
  • Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther. 1975 Oct;18(4):425–432. [PubMed]
  • Webb DB, Roberts DE, Williams JD, Asscher AW. Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function. J Antimicrob Chemother. 1986 Nov;18 Suppl NaN:83–87. [PubMed]
  • Wise R, Donovan IA. Tissue penetration and metabolism of ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):103–107. [PubMed]
  • Wood AJ, Vestal RE, Wilkinson GR, Branch RA, Shand DG. Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther. 1979 Jul;26(1):16–20. [PubMed]
  • Yuk JH, Nightingale CH, Sweeney KR, Quintiliani R, Lettieri JT, Frost RW. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding. Antimicrob Agents Chemother. 1989 Jul;33(7):1118–1120. [PubMed]